HealthDay News — Improper disinfection and not following contamination prevention protocols are among the 9 violations found by US Food and Drug Administration inspectors at a Baltimore plant that had to discard up to 15 million doses of the Janssen COVID-19 vaccine and was ordered to temporarily halt all production.
The inspection at the Emergent BioSolutions plant — a subcontractor of Johnson & Johnson — was conducted after reports that workers had contaminated a batch of Janssen vaccine doses with the harmless virus used to deliver the AstraZeneca vaccine, which is also made at the plant.
The violations included: not properly disinfecting the factory and its equipment, not following procedures meant to prevent contamination of doses and to ensure the strength and purity of the vaccines made at the plant, improperly trained employees, and problems with the design of the building, according to the inspection completed Tuesday.
The FDA said it has not authorized Emergent to distribute any Janssen vaccine doses and that no vaccine made at the plant has been released for use in the United States.
The agency said it was working with Emergent to fix the problems. Earlier this month, the FDA said the AstraZeneca vaccine could no longer be made at the plant to reduce the risk for cross-contamination with the Janssen vaccine.